---
figid: PMC8992566__cdr-3-742.fig.4
figtitle: 'Resistance to second generation antiandrogens in prostate cancer: pathways
  and mechanisms'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC8992566
filename: cdr-3-742.fig.4.jpg
figlink: /pmc/articles/PMC8992566/figure/fig4/
number: F4
caption: 'Mechanisms of enzalutamide and abiraterone acetate resistance in prostate
  cancer cells. Aberrant activation of PI3K/Akt pathway overexpressing p110β with
  loss of PTEN gene. Interaction of p85α subunits with Src kinase activates MAPK.
  Activated Akt overexpresses N-Myc, FOXO, ONECUT2 and EZH2 leads to activation of
  HIF1α, SMAD3, SOX2, and Nanog through suppressing TP53 and RB1. AR in the presence
  of hnRPA-1 forms AR-Vs and activates NF-κB signaling which in turn up-regulates
  IL-6 gene expression. Long-term exposure to antiandrogens significantly increases
  GR expression. Interaction of aberrant β-catenin of Wnt signaling to AR leads to
  expression target genes involved prostate cancer cell proliferation, tumor growth,
  stem cell marker expression, and chemotherapy drug resistance. Interaction of these
  genes with each other and with AR promotes enzalutamide/abiraterone acetate mediated
  neuroendocrine prostate cancer (NEPC) and castration resistant prostate cancer (CRPC)
  formation. PI3K: phosphatidylinositol-3 kinase; PTEN: phosphatase and tensin homolog;
  MAPK: mitogen-activated protein kinase; EZH2: enhancer of zeste homolog 2; HIF1α:
  hypoxia-inducible factors- α; SOX2: SRY-box transcription factor 2; TP53: tumor
  protein 53; RB1: retinoblastoma1; hnRPA-1: heterogeneous nuclear ribonucleoprotein
  A1; IL-6: interleukin-6; AR-vs: Androgen receptor variants; AR: androgen receptor;
  GR: glucocorticoid receptor; CRPC: castration resistant prostate cancer; NEPC: neuroendocrine
  prostate cancer; BCAF: B-cell activating factor; LT: Lymphotoxin-β; AURKA: Aurora
  kinase A'
papertitle: 'Resistance to second generation antiandrogens in prostate cancer: pathways
  and mechanisms.'
reftext: Shiv Verma, et al. Cancer Drug Resist. 2020;3(4):742-761.
year: '2020'
doi: 10.20517/cdr.2020.45
journal_title: Cancer Drug Resistance
journal_nlm_ta: Cancer Drug Resist
publisher_name: OAE Publishing Inc.
keywords: Prostate cancer | second-generation antiandrogens | androgen receptor |
  castration resistance prostate cancer
automl_pathway: 0.9126174
figid_alias: PMC8992566__F4
figtype: Figure
redirect_from: /figures/PMC8992566__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8992566__cdr-3-742.fig.4.html
  '@type': Dataset
  description: 'Mechanisms of enzalutamide and abiraterone acetate resistance in prostate
    cancer cells. Aberrant activation of PI3K/Akt pathway overexpressing p110β with
    loss of PTEN gene. Interaction of p85α subunits with Src kinase activates MAPK.
    Activated Akt overexpresses N-Myc, FOXO, ONECUT2 and EZH2 leads to activation
    of HIF1α, SMAD3, SOX2, and Nanog through suppressing TP53 and RB1. AR in the presence
    of hnRPA-1 forms AR-Vs and activates NF-κB signaling which in turn up-regulates
    IL-6 gene expression. Long-term exposure to antiandrogens significantly increases
    GR expression. Interaction of aberrant β-catenin of Wnt signaling to AR leads
    to expression target genes involved prostate cancer cell proliferation, tumor
    growth, stem cell marker expression, and chemotherapy drug resistance. Interaction
    of these genes with each other and with AR promotes enzalutamide/abiraterone acetate
    mediated neuroendocrine prostate cancer (NEPC) and castration resistant prostate
    cancer (CRPC) formation. PI3K: phosphatidylinositol-3 kinase; PTEN: phosphatase
    and tensin homolog; MAPK: mitogen-activated protein kinase; EZH2: enhancer of
    zeste homolog 2; HIF1α: hypoxia-inducible factors- α; SOX2: SRY-box transcription
    factor 2; TP53: tumor protein 53; RB1: retinoblastoma1; hnRPA-1: heterogeneous
    nuclear ribonucleoprotein A1; IL-6: interleukin-6; AR-vs: Androgen receptor variants;
    AR: androgen receptor; GR: glucocorticoid receptor; CRPC: castration resistant
    prostate cancer; NEPC: neuroendocrine prostate cancer; BCAF: B-cell activating
    factor; LT: Lymphotoxin-β; AURKA: Aurora kinase A'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK4
  - AURKA
  - MYCN
  - TP53
  - RB1
  - RBM45
  - SOX2
  - NANOG
  - SMAD3
  - SRC
  - FGR
  - FYN
  - YES1
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - ABCC6
  - FOXC1
  - PAK3
  - EZH2
  - AR
  - ONECUT2
  - CD40
  - STAT3
  - LTB
  - MAP3K14
  - MAP4K4
  - CHUK
  - CUX1
  - NFKB2
  - OAS3
  - PMEL
  - SART3
  - TPX2
  - SND1
  - ASCC2
  - IL6
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - CTNNB1
---
